Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 14.0% in January

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 108,462 shares, a decrease of 14.0% from the December 31st total of 126,115 shares. Based on an average daily trading volume, of 83,283 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.6% of the company’s stock are sold short. Currently, 1.6% of the company’s stock are sold short. Based on an average daily trading volume, of 83,283 shares, the days-to-cover ratio is presently 1.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Lixte Biotechnology Stock Down 4.7%

Lixte Biotechnology stock opened at $3.22 on Thursday. The firm has a market cap of $24.09 million, a P/E ratio of -2.73 and a beta of 0.93. The business has a fifty day moving average of $3.81 and a two-hundred day moving average of $4.25. Lixte Biotechnology has a twelve month low of $0.64 and a twelve month high of $6.26.

Lixte Biotechnology (NASDAQ:LIXT) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.33) EPS for the quarter.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.